Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...

Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

A Big Chalk Analytics survey of 4,511 U.S. shoppers in spring of 2025 showed that 11.2% of adults are using GLP-1 drugs, and ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.

CHICAGO — Tariffs, the rise of GLP-1 medications and concerns about ultra-processed foods (UPFs) remain some of the major ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.